424 related articles for article (PubMed ID: 34923180)
1. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
[TBL] [Abstract][Full Text] [Related]
4. Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients.
Dang Z; Jiang L; Huang F
Int J Clin Pharmacol Ther; 2023 Oct; 61(10):423-429. PubMed ID: 37548453
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.
Guo Y; Ren Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
BMC Cancer; 2022 Mar; 22(1):270. PubMed ID: 35287627
[TBL] [Abstract][Full Text] [Related]
6. Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Lai X; Wang A
Comput Intell Neurosci; 2022; 2022():6336107. PubMed ID: 36052044
[TBL] [Abstract][Full Text] [Related]
7. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients.
Zhu C; Dai B; Zhan H; Deng R
Ir J Med Sci; 2023 Jun; 192(3):1065-1071. PubMed ID: 35996068
[TBL] [Abstract][Full Text] [Related]
9. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy of aparatinib and carrilizumab combined with transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma.
Chen C; Duan XT; Li GY; Hao XJ; Wang WL; Shen YF; Zhang SH
Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4135-4144. PubMed ID: 37203839
[TBL] [Abstract][Full Text] [Related]
11. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
12. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Can J Gastroenterol Hepatol; 2022; 2022():7982118. PubMed ID: 35586608
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract][Full Text] [Related]
17. Propensity score matching analysis of efficacy of drug-eluting beads (DEB)-TACE loaded with different drugs in the treatment of hepatocellular carcinoma.
Yang L; Wang H; Li S; Gan G; Deng W; Chang Y; Zhang L
Am J Transl Res; 2023; 15(2):1526-1532. PubMed ID: 36915718
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
Hou C; Xiong B; Zhou L; Fei Y; Shi C; Zhu X; Xie T; Wu Y
BMC Cancer; 2024 Mar; 24(1):387. PubMed ID: 38539150
[TBL] [Abstract][Full Text] [Related]
19. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Zhang K; Sun X; Xie F; Jian W; Li C
J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
